Search research articles
Contact Us
Filters
Showing results (31-40 of 82) with videos related to
Page
of 9
Sort By:
Pharmacoeconomics
|
May 27, 1999
The burden of illness of hypopituitary adults with growth hormone deficiency
L Hakkaart-van Roijen, A Beckers, A Stevenaert, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
April 13, 1991
[Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine]
L L Martens, F F Rutten, J L Kuijpens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1994
Measurement and valuation of quality of life in economic appraisal of cancer treatment
C A Uyl-de Groot, F F Rutten, G J Bonsel
Pharmacoeconomics
|
June 6, 1996
Colony-stimulating factors and peripheral blood progenitor cell transplantation. Benefits and costs
C A Uyl-de Groot, P C Huijgens, F F Rutten
Pharmacoeconomics
|
March 31, 2001
Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective
C Chevat, B M Peña, M J Al, et al.
Journal of Medical Genetics
|
October 10, 1997
Cost effectiveness of DNA diagnosis for four monogenic diseases
A A van der Riet, B A van Hout, F F Rutten
The American Journal of Cardiology
|
March 20, 1990
Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands
L L Martens, F F Rutten, D W Erkelens, et al.
Pharmacoeconomics
|
April 8, 1993
Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model
B A van Hout, G Wielink, G J Bonsel, et al.
The American Journal of Medicine
|
October 16, 1989
Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine
L L Martens, F F Rutten, D W Erkelens, et al.
Journal of Health Economics
|
May 8, 1995
The friction cost method for measuring indirect costs of disease
M A Koopmanschap, F F Rutten, B M van Ineveld, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 82) with videos related to
Sort By:
Page
of 9
Pharmacoeconomics
|
May 27, 1999
The burden of illness of hypopituitary adults with growth hormone deficiency
L Hakkaart-van Roijen, A Beckers, A Stevenaert, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
April 13, 1991
[Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine]
L L Martens, F F Rutten, J L Kuijpens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1994
Measurement and valuation of quality of life in economic appraisal of cancer treatment
C A Uyl-de Groot, F F Rutten, G J Bonsel
Pharmacoeconomics
|
June 6, 1996
Colony-stimulating factors and peripheral blood progenitor cell transplantation. Benefits and costs
C A Uyl-de Groot, P C Huijgens, F F Rutten
Pharmacoeconomics
|
March 31, 2001
Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective
C Chevat, B M Peña, M J Al, et al.
Journal of Medical Genetics
|
October 10, 1997
Cost effectiveness of DNA diagnosis for four monogenic diseases
A A van der Riet, B A van Hout, F F Rutten
The American Journal of Cardiology
|
March 20, 1990
Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands
L L Martens, F F Rutten, D W Erkelens, et al.
Pharmacoeconomics
|
April 8, 1993
Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model
B A van Hout, G Wielink, G J Bonsel, et al.
The American Journal of Medicine
|
October 16, 1989
Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine
L L Martens, F F Rutten, D W Erkelens, et al.
Journal of Health Economics
|
May 8, 1995
The friction cost method for measuring indirect costs of disease
M A Koopmanschap, F F Rutten, B M van Ineveld, et al.
Page
of 9